Modality
mAb
MOA
WEE1i
Target
CFTR
Pathway
Ferroptosis
IPF
Development Pipeline
Preclinical
~Jun 2015
→ ~Sep 2016
Phase 1
~Dec 2016
→ ~Mar 2018
Phase 2
Jun 2018
→ Apr 2030
Phase 2Current
NCT03262347
2,843 pts·IPF
2021-05→2025-05·Terminated
NCT04057461
1,733 pts·IPF
2018-06→2030-04·Not yet recruiting
4,576 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-05-0411mo agoPh2 Data· IPF
2030-04-074.0y awayPh2 Data· IPF
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P2
Not yet…
P2
Termina…
Catalysts
Ph2 Data
2025-05-04 · 11mo ago
IPF
Ph2 Data
2030-04-07 · 4.0y away
IPF
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03262347 | Phase 2 | IPF | Terminated | 2843 | OS |
| NCT04057461 | Phase 2 | IPF | Not yet recr... | 1733 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Datoglumide | AbbVie | Approved | CFTR | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| Sovarelsin | BioMarin | Phase 2 | CFTR | |
| Fixatuximab | Legend Biotech | Preclinical | CFTR |